Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2026)

Cogent Biosciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $52.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 110.4% year-over-year to $52.5 million; the TTM figure through Mar 2026 stood at $905.8 million (up 3471.2% YoY), while the FY2025 annual figure was $878.2 million, up 309.53% from the prior year.
• Cash from Financing Activities was $52.5 million for Q1 2026 at Cogent Biosciences, down from $588.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $588.7 million in Q4 2025 to a low of -$256000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $92.0 million across 5 years, with a median of $13.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 100.16% in 2024, then soared 2264011.54% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $315000.0 in 2022, then jumped by 217.46% to $1.0 million in 2023, then tumbled by 97.4% to $26000.0 in 2024, then jumped by 2264011.54% to $588.7 million in 2025, then tumbled by 91.08% to $52.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $52.5 million (Q1 2026), $588.7 million (Q4 2025), and $217.4 million (Q3 2025), per Business Quant data.